GLP-1 Receptor Agonists Reduce the Risk of Hepatocellular Carcinoma and Cirrhosis in Patients With Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes

被引：0
|
作者：
Alsakarneh, Saqr [1 ]
Madi, Mahmoud [2 ]
Abuassi, Mohammad [3 ]
Jaber, Fouad [1 ]
Khadra, Majd [4 ]
Numan, Laith [2 ]
Syn, Wing-Kin [2 ]
机构：
[1] Univ Missouri, Kansas City Sch Med, Kansas City, MO USA
[2] St Louis Univ, Sch Med, St Louis, MO USA
[3] Univ Cent Florida, HCA Healthcare GME, Gainesville, FL USA
[4] Wayne State Univ, Detroit Med Ctr, Detroit, MI USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 10S期
关键词：
D O I：
10.14309/01.ajg.0001036968.88400.f3
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S1900
引用
收藏
页码：S1364 / S1364
页数：1
相关论文
共 50 条
  • [1] GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease
    Liu, Jia
    Wang, Guang
    Jia, Yumei
    Xu, Yuan
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2015, 31 (04) : 329 - 335
  • [2] GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
    Lee, Jinmi
    Hong, Seok-Woo
    Rhee, Eun-Jung
    Lee, Won-Young
    DIABETES & METABOLISM JOURNAL, 2012, 36 (04) : 262 - 267
  • [3] GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
    Nevola, Riccardo
    Epifani, Raffaella
    Imbriani, Simona
    Tortorella, Giovanni
    Aprea, Concetta
    Galiero, Raffaele
    Rinaldi, Luca
    Marfella, Raffaele
    Sasso, Ferdinando Carlo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (02)
  • [4] Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
    Zhu, Yuan
    Xu, Jiao
    Zhang, Dong
    Mu, Xingyu
    Shi, Yi
    Chen, Shangtao
    Wu, Zengxiang
    Li, Shuangqing
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [5] GLP-1 receptor agonists and cirrhosis risk in type 2 diabetes mellitus
    Pavlicek, Vojtech
    DIABETOLOGIE, 2024, 20 (08): : 897 - 898
  • [6] Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case-control study
    Chang, Kai-Cheng
    Kuo, Fan-Chi
    Yang, Chen-Yi
    Yang, Chun-Ting
    Ou, Huang-Tz
    Kuo, Shihchen
    CARDIOVASCULAR DIABETOLOGY, 2024, 23 (01)
  • [7] Risk of Hepatocellular Carcinoma in Patients with Non-alcoholic Fatty Liver Disease
    Kim, Dong Yun
    Park, Jun Yong
    KOREAN JOURNAL OF GASTROENTEROLOGY, 2021, 78 (01): : 69 - 71
  • [8] NON-ALCOHOLIC FATTY LIVER DISEASE AS A RISK FACTOR FOR HEPATOCELLULAR CARCINOMA IN THE ABSENCE OF CIRRHOSIS
    Harrington, Allison
    Rufin, Milna
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2018, 33 : S567 - S568
  • [9] Identifying risk factors for the development of hepatocellular carcinoma in patients with cirrhosis and non-alcoholic fatty liver disease
    Chin, J.
    Bertot, L.
    Jeffrey, G.
    Garas, G.
    Wallace, M.
    Smith, B.
    Macquillan, G.
    Adams, L.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 : 39 - 39
  • [10] Risk Stratification for Hepatocellular Carcinoma in Patients with Non-alcoholic Fatty Liver Disease
    Truong E.
    Han C.
    Muthiah M.
    Noureddin M.
    Current Hepatology Reports, 2023, 22 (1) : 1 - 8
12345